Ramucirumab - Eli Lilly

Drug Profile

Ramucirumab - Eli Lilly

Alternative Names: Anti-flk-1 monoclonal antibody - ImClone; Anti-KDR monoclonal antibody - ImClone; Anti-VEGFR 2 monoclonal antibody - ImClone; Cyramza; IMC-1121; IMC-1121-B; IMC-1C11 - ImClone; LY-3009806; Ramcilumab; ramsilmab; Ramsilomab; Ramsylmab; Ramsylumab; Sairamza; Silamza

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dyax
  • Developer AstraZeneca; Dana-Farber Cancer Institute; Eli Lilly; Merck Sharp & Dohme; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Gastric cancer; Non-small cell lung cancer
  • Phase III Hepatocellular carcinoma; Oesophageal cancer; Urogenital cancer
  • Phase II Biliary cancer; Carcinoid tumour
  • Phase I Solid tumours
  • No development reported Breast cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 08 Dec 2017 Interim efficacy and adverse events data from a phase III RAINFALL trial in Gastric cancer released by Eli Lilly
  • 08 Dec 2017 Eli Lilly completes enrolment in its phase III RAINFALL trial in Gastric cancer in Argentina, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Japan, Mexico, Netherlands, Poland, Puerto Rico, Russia, Spain, United Kingdom and USA (IV) before December 2017
  • 08 Dec 2017 Eli Lilly plans a clinical trials for Cancer (Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top